Indivior Pharmaceuticals, Inc. — Form 8-K
Filed August 3, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 72/100
What the filing says
Indivior Pharmaceuticals and Supernus Pharmaceuticals have agreed to merge in an all-stock transaction dated August 1, 2026. Supernus shareholders will receive 1.5401 Indivior shares per Supernus share (Exchange Ratio). The combined company will be renamed Supernus, Inc., trade under Supernus's existing ticker, and be governed by a board split equally between Indivior and Supernus designees with an Indivior designee as chair. Both boards unanimously approved the merger; stockholder approval required from both companies.
Why this rating
Merger of equals combining two ~$1.8B pharmaceutical companies materially reshapes ownership structure and governance but terms appear negotiated fairly; lacks acquisition premium but creates combined enterprise. Moderate strategic significance for size and structure, but no clear value accretion or destruction evident from agreement alone.
See more from August 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.